| Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
|
Jun '22
|
Lord Sugar
|
|
Acl / NMS:ACLX |
£17.47
|
£114.29
|
554.21%
|
£457,945.08
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Candel Therapeutics / NGM:CADL |
£1.40
|
£4.98
|
255.71%
|
£249,000.00
|
|
May '22
|
Lord Reay
|
|
Novo Nordisk As / NYQ:NVO |
£56.40
|
£140.80
|
149.67%
|
£174,767.27**
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Tg Therapeutics / NCM:TGTX |
£15.05
|
£26.94
|
79.00%
|
£125,302.33
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Fortress Biotech / NCM:FBIO |
£1.92
|
£3.28
|
70.83%
|
£119,583.33
|
|
Mar '24
|
Lord Petitgas
|
|
Royalty Pharma / NMS:RPRX |
£30.08
|
£45.87
|
52.49%
|
£106,745.34
|
|
May '22
|
Lord Triesman
|
|
Blue / NMS:BLUE |
£3.39
|
£4.97
|
46.61%
|
£102,625.36
|
|
Jul '25
|
Lord Fink
|
|
Avacta Group / LSE:AVCT.L |
£51.50
|
£72.00
|
39.81%
|
£97,864.08
|
|
Nov '21
|
Lord Sherbourne of Didsbury
|
|
Novo Nordisk As / NYQ:NVO |
£56.71
|
£70.73
|
24.73%
|
£87,313.29**
|
|
Nov '24
|
Lord Moynihan of Chelsea
|
|
Sab Biotherapeutics / NCM:SABS |
£3.95
|
£4.59
|
16.20%
|
£81,341.77
|
|
Dec '22
|
Lord Hintze
|
|
Atai Life Sciences / NGM:ATAI |
£3.48
|
£3.87
|
11.21%
|
£77,844.83**
|
|
Apr '21
|
Baroness Deech
|
|
Novo Nordisk As / NYQ:NVO |
£36.35
|
£38.02
|
4.59%
|
£73,215.96
|
|
Apr '22
|
Lord Hylton
|
|
Genus / LSE:GNS.L |
£2,678.00
|
£2,695.00
|
0.63%
|
£70,444.36
|
|
Aug '23
|
Lord Nash
|
|
Relay / NGM:RLAY |
£10.62
|
£10.55
|
-0.66%
|
£69,538.61
|
|
Jun '16
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£47.80
|
£45.10
|
-5.65%
|
£66,046.02
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Mustang Bio / NCM:MBIO |
£1.04
|
£0.94
|
-9.13%
|
£63,605.77
|
|
Mar '17
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£54.95
|
£45.10
|
-17.93%
|
£57,452.23
|
|
Mar '14
|
Lord Glendonbrook
|
|
Bb Biotech / EBS:BION.SW |
£33.36
|
£27.20
|
-18.47%
|
£57,074.34**
|
|
May '23
|
Lord Stevens of Ludgate
|
|
Avacta Group / LSE:AVCT.L |
£112.00
|
£72.00
|
-35.71%
|
£45,000.00
|
|
Jan '21
|
Lord Spencer of Alresford
|
|
Immupharma / LSE:IMM.L |
£12.65
|
£6.64
|
-47.51%
|
£36,743.08
|
|
Apr '24
|
Lord Grabiner
|
|
Novo Nordisk As / NYQ:NVO |
£127.46
|
£64.73
|
-49.22%
|
£35,549.19**
|
|
Mar '24
|
Lord Petitgas
|
|
Moderna / NMS:MRNA |
£111.98
|
£53.39
|
-52.32%
|
£33,374.71
|
|
Nov '23
|
Lord Mance
|
|
Novo Nordisk As / NYQ:NVO |
£101.69
|
£38.02
|
-62.61%
|
£26,171.70
|
|
Apr '22
|
Lord Spencer of Alresford
|
|
Oxford Nanopore / LSE:ONT.L |
£320.00
|
£118.20
|
-63.06%
|
£25,856.25
|
|
Apr '24
|
Lord Willoughby de Broke
|
|
Novo Nordisk As / NYQ:NVO |
£122.75
|
£38.02
|
-69.03%
|
£21,681.47
|
|
May '24
|
Lord Londesborough
|
|
Novo Nordisk As / NYQ:NVO |
£134.66
|
£38.02
|
-71.77%
|
£19,763.85
|
|
Sep '21
|
Lord Darzi of Denham
|
|
Oxford Nanopore / LSE:ONT.L |
£612.60
|
£118.20
|
-80.71%
|
£13,506.37
|
|
Oct '15
|
Lord Hayward
|
|
Sage / NGM:SAGE |
£46.11
|
£8.68
|
-81.18%
|
£13,177.19
|
|
May '11
|
Lord Glendonbrook
|
|
Mesoblast / NMS:MESO |
£101.20
|
£15.07
|
-85.11%
|
£10,423.91
|
|
May '20
|
Lord Wolfson of Aspley Guise
|
|
Adc Therapeutics / NYQ:ADCT |
£30.00
|
£4.35
|
-85.50%
|
£10,150.00
|
|
Apr '19
|
Lord Nash
|
|
Eq / NCM:EQ |
£8.20
|
£0.69
|
-91.59%
|
£5,890.24**
|
|
Mar '23
|
Baroness Shields
|
|
Benevolentai / AMS:BAI.AS |
£2.46
|
£0.09
|
-96.14%
|
£2,703.25**
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Avenue Therapeutics / NCM:ATXI |
£12.00
|
£0.23
|
-98.08%
|
£1,341.67
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Adaptimmune / NMS:ADAP |
£1.47
|
£0.03
|
-98.28%
|
£1,207.14
|
|
Dec '22
|
Lord Hintze
|
|
Affimed / NGM:AFMD |
£21.20
|
£0.18
|
-99.14%
|
£599.29
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.